Search - tctmd.com

Displaying 61 - 80 of 269

Sort: Relevancy | Date

News Industry News

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

December 06, 2017

News Conference News TCT 2017

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

Todd Neale

November 01, 2017

News Industry News

STENTYS Completes Enrollment in the Study Assessing the Safety and Efficacy of Xposition S in Left Main Artery Lesions

July 28, 2017

News Features EuroPCR 2017

Seven Next-Generation Bioresorbable Scaffolds Show Promise but Face Major Hurdles

Yael L. Maxwell

June 01, 2017

News Industry News

STENTYS: Follow-Up of the APPOSITION IV and OPEN II Clinical Trials at Respectively 3 and 4 Years Confirms the Initial Positive Study Outcomes

May 25, 2017

News Conference News EuroPCR 2017

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Michael O'Riordan

May 18, 2017

News Industry News

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

May 16, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ISET 2017

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

Caitlin E. Cox

February 17, 2017

News Daily News

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

L.A. McKeown

February 08, 2017

News Daily News

After EXCEL and NOBLE, New Meta-analysis Revisits PCI vs Surgery for Unprotected Left Main CAD

Michael O'Riordan

December 14, 2016

News Industry News

Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial of MiStent In Japan

November 29, 2016

News Conference News TCT 2016

Novel SES Fails to Match Xience EES for Chronic Total Occlusions

Yael L. Maxwell

November 08, 2016

News Industry News

Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016

November 03, 2016

News Industry News TCT 2016

Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions

November 02, 2016

News Conference News TCT 2016

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

Yael L. Maxwell

October 31, 2016

News Industry News

TCT 2016 First Report Investigations Examine Potential For Novel Bioresorbable Stent Technologies

October 31, 2016

News Industry News

Very Thin-Strut Biodegradable Polymer Everolimus-Eluting And Sirolimus-Eluting Stents Shown To Be Non-Inferior To Durable Polymer Zotarolimus-Eluting Stents In All-Comers With Coronary Artery Disease

October 30, 2016

News Conference News TCT 2016

DES With Biodegradable Polymers Stand Up Well Against Durable-Polymer Stents in the Short Term

Todd Neale

October 30, 2016

Advertisement

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

STENTYS Completes Enrollment in the Study Assessing the Safety and Efficacy of Xposition S in Left Main Artery Lesions

Seven Next-Generation Bioresorbable Scaffolds Show Promise but Face Major Hurdles

STENTYS: Follow-Up of the APPOSITION IV and OPEN II Clinical Trials at Respectively 3 and 4 Years Confirms the Initial Positive Study Outcomes

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Bioresorbable Scaffolds for PAD: Does the Strategy Have Legs?

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

After EXCEL and NOBLE, New Meta-analysis Revisits PCI vs Surgery for Unprotected Left Main CAD

Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial of MiStent In Japan

Novel SES Fails to Match Xience EES for Chronic Total Occlusions

Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016

Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions

New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts

TCT 2016 First Report Investigations Examine Potential For Novel Bioresorbable Stent Technologies

Very Thin-Strut Biodegradable Polymer Everolimus-Eluting And Sirolimus-Eluting Stents Shown To Be Non-Inferior To Durable Polymer Zotarolimus-Eluting Stents In All-Comers With Coronary Artery Disease

DES With Biodegradable Polymers Stand Up Well Against Durable-Polymer Stents in the Short Term

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content